Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
enGene Therapeutics Inc. - Common Stock
(NQ:
ENGN
)
1.625
+0.025 (+1.56%)
Streaming Delayed Price
Updated: 11:28 AM EDT, Jun 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about enGene Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
↗
May 30, 2026
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Via
The Motley Fool
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
↗
May 30, 2026
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
Via
The Motley Fool
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
May 29, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 19, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
↗
May 15, 2026
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
Via
The Motley Fool
Topics
Regulatory Compliance
Unusual volume stocks are being observed in Monday's session.
↗
May 11, 2026
Via
Chartmill
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
↗
May 08, 2026
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk...
Via
MarketBeat
Which stocks are experiencing notable movement on Thursday?
↗
May 07, 2026
Via
Chartmill
Top stock movements in today's session.
↗
May 07, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
May 07, 2026
Via
Chartmill
Which stocks are moving before the opening bell on Thursday?
↗
May 07, 2026
Via
Chartmill
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 07, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene Announces Name Change to enGene Therapeutics Inc.
April 07, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
↗
March 21, 2026
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Via
The Motley Fool
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
March 09, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in Upcoming Investor Conferences
February 20, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
January 20, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports Full Year 2025 Financial Results and Provides Business Update
December 22, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
December 02, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
enGene Holdings Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 18, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 13, 2025
Via
Benzinga
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
November 13, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene Announces Proposed Public Offering of Common Shares
November 12, 2025
From
enGene Holdings Inc.
Via
Business Wire
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session.
↗
November 11, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
November 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
↗
November 11, 2025
Via
Benzinga
Topics
Stocks
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
